HM Payson & Co’s Repare Therapeutics RPTX Stock Holding History

HM Payson & Co’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	–	–	1154
2021 Q1	$0	Hold	2	–	–	﹤0.01%	1179
2020 Q4	$0	Hold	2	–	–	﹤0.01%	1147
2020 Q3	$0	Buy	+2	New	+$53	﹤0.01%	1069

Other funds holding RPTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

HM Payson & Co's RPTX Position: Q2 2021 in Review

HM Payson & Co sold out of Repare Therapeutics (RPTX) in Q2 2021, closing a stake of 2 shares.

HM Payson & Co first reported a position in RPTX in Q3 2020 and held it in 3 quarters. The position peaked at $0 in Q1 2021. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2021.

HM Payson & Co reported no remaining Repare Therapeutics position as of Q2 2021 after selling out during the quarter.
HM Payson & Co sold 2 Repare Therapeutics shares in Q2 2021.
HM Payson & Co first reported a position in Repare Therapeutics in Q3 2020 and held it in 3 quarters.
HM Payson & Co's Repare Therapeutics position peaked at $0 in Q1 2021.
61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.